TrialBritish journal of cancer2010

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

A Santoro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.